Selumetinib + Pembrolizumab
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors
Trial Timeline
Mar 18, 2019 → Jun 28, 2022
NCT ID
NCT03833427About Selumetinib + Pembrolizumab
Selumetinib + Pembrolizumab is a phase 1 stage product being developed by Merck for Advanced/Metastatic Solid Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT03833427. Target conditions include Advanced/Metastatic Solid Tumors.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Solid Tumors were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03833427 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors